Douglas E Brenneman from North Wales, PA, age 79

Name / Title

Company / Classification

Phones & Addresses

Mr. Douglas Brenneman
Secretary-Treasurer

Expressway Ford Lincoln Sales
Auto Dealers - New Cars

1554 Haysville Rd, New Hamburg, ON N3A 1A3
(519)6623900, (519)6623904

Douglas Brenneman
Director, Founder, Founder, Chief Scientific Officer

Advanced Neural Dynamics, Inc
Medical Research

3805 Old Easton Rd, Gardenville, PA 18902

Douglas Brenneman
Secretary-Treasurer

Expressway Ford Lincoln Sales
Auto Dealers - New Cars

(519)6623900, (519)6623904

Medicine Doctors

Douglas W. Brenneman

view source

Specialties:

Family Medicine, Osteopathic Manipulative Medicine

Work:

Family Medicine Associates
2500 Delta Rd, Brogue, PA 17309
(717)9278434 (phone), (717)9276274 (fax)

Education:

Medical School
Philadelphia College of Osteopathic Medicine
Graduated: 2001

Procedures:

Allergen Immunotherapy
Arthrocentesis
Destruction of Benign/Premalignant Skin Lesions
Electrocardiogram (EKG or ECG)
Hearing Evaluation
Osteopathic Manipulative Treatment
Vaccine Administration

Conditions:

Acute Pharyngitis
Acute Sinusitis
Acute Upper Respiratory Tract Infections
Allergic Rhinitis
Anxiety Phobic Disorders

Languages:

English

Description:

Dr. Brenneman graduated from the Philadelphia College of Osteopathic Medicine in 2001. He works in Brogue, PA and specializes in Family Medicine and Osteopathic Manipulative Medicine. Dr. Brenneman is affiliated with Memorial Hospital and Wellspan York Hospital.

Us Patents

Activity Dependent Neurotrophic Factor Iii (Adnf Iii)
view source
US Patent:

6613740, Sep 2, 2003
Filed:

Nov 6, 1998
Appl. No.:

09/187330
Inventors:

Illana Gozes - Ramat, Hasharon, IL
Douglas E. Brenneman - Damascus MD
Merav Bassan - Givat-Poleg, Natanya, IL
Rachel Zamostiano - Hod-Hasharon, IL
Assignee:

Ramot University Authority for Applied Research and Industrial Development Ltd. - Tel Aviv
The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC
International Classification:

A61K 3800
US Classification:

514 12, 514 2, 514 13, 514 14, 514 15, 514 16, 530324, 530325, 530326, 530327, 530328, 530350
Abstract:

The present invention relates generally to Activity Dependent Neurotrophic Factor III (ADNF III), also known as Activity Dependent Neuroprotective Protein (ADNP). More particularly, the present invention relates to nucleic acid sequences encoding ADNF III polypeptides; ADNF III polypeptides encoded by such nucleic acid sequences; antibodies to ADNF III polypeptides; and methods of using such ADNF III polypeptides for the treatment of neurological deficiencies and for the prevention of cell death associated with (1) gp120, the envelope protein from HIV; (2) N-methyl- -aspartic acid (excito-toxicity); (3) tetrodotoxin (blockage of electrical activity); and (4) -amyloid peptide, a substance related to neuronal degeneration in Alzheimers disease.

Combination Therapy With Vip Antagonist
view source
US Patent:

6630124, Oct 7, 2003
Filed:

Jan 9, 2002
Appl. No.:

09/807557
Inventors:

Illana Gozes - Ramat Hasharon, IL
Mati Fridkin - Rehovot, IL
Edgar Gelber - Petach Tikva, IL
Terry W. Moody - Germantown MD
Douglas C. Brenneman - Damascus MD
Assignee:

Ramot-University Authority for Applied Research and Industrial Development Ltd. - Tel-Aviv
Yeda Research and Development Co. Ltd. - Rehovot
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:

A61K 5100
US Classification:

424 169, 424 111, 424 91, 530324, 514 12
Abstract:

The present invention relates to combination therapy using a pharmaceutical composition comprising a polypeptide which is an antagonist of the vasoactive intestinal polypeptide (VIP) and a chemotherapeutic agent. Methods of using the pharmaceutical composition are also disclosed.

Methods Of Inhibiting Cancer Cells With Adnf Iii Antisense Oligonucleotides
view source
US Patent:

6649411, Nov 18, 2003
Filed:

Jul 30, 1999
Appl. No.:

09/364609
Inventors:

Illana Gozes - Ramat-Hasharon, IL
Douglas E. Brenneman - Damascus MD
Rachel Zamostiano - Hod-Hasharon, IL
Edgar Gelber - Petach-Tikvah, IL
Albert Pinhasov - Tel-Aviv, IL
Merav Bassan - Netanya, IL
Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC
Ramot at Tel-Aviv University Ltd. - Tel-Aviv
International Classification:

C12N 500
US Classification:

435375, 435 6, 435 911, 435377, 435455, 536 231, 536 245
Abstract:

The present invention provides methods of using antisense ADNF III oligonucleotides to inhibit the growth of pathologically proliferating cells. The invention also provides methods and kits for using ADNF III nucleic acid probes to detect the presence of pathologically proliferating cells in human tissues.

Prevention Of Fetal Alcohol Syndrome And Neuronal Cell Death With Adnf Polypeptides
view source
US Patent:

6933277, Aug 23, 2005
Filed:

Mar 12, 1999
Appl. No.:

09/267511
Inventors:

Douglas E. Brenneman - Damascus MD, US
Catherine Y. Spong - Arlington VA, US
Illana Gozes - Ramat Hasharon, IL
Merav Bassan - Natania, IL
Rachel Zamostiano - Hod Hashron, IL
Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC
Ramot University Authority for Applied Research and Industrial Development, Ltd. - Tel Aviv
International Classification:

A61K038/00
A61K039/00
A61K038/24
A01N037/18
C07K001/00
US Classification:

514 12, 514 2, 4241841, 4241851, 4241981, 530350, 530399
Abstract:

This invention relates to a method for reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with an ADNF polypeptide. In particular, the present invention relates to a method of reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with a combination of ADNF I and ADNF III polypeptides. The present invention further relates to a method for reducing neuronal cell death by contacting neuronal cells with a combination of ADNF I and ADNF III polypeptides. Still further, the present invention relates to a pharmaceutical composition comprising a combination of ADNF I and ADNF III polypeptides.

Activity Dependent Neurotrophic Factor Iii (Adnf Iii)
view source
US Patent:

7264947, Sep 4, 2007
Filed:

Jul 17, 2003
Appl. No.:

10/623272
Inventors:

Illana Gozes - Hasharon, IL
Douglas E. Brenneman - Damascus MD, US
Merav Bassan - Natanya, IL
Rachel Zamostiano - Hod-Hasharon, IL
Assignee:

United States of America, as represented by the Secretary of the Department of Health and Human Services - Washington DC
International Classification:

C12P 21/06
C12Q 1/68
C12N 5/00
C12N 15/00
US Classification:

435 691, 536 235, 435 6, 4353201, 435325
Abstract:

The present invention relates generally to Activity Dependent Neurotrophic Factor III (ADNF III), also known as Activity Dependent Neuroprotective Protein (ADNP). More particularly, the present invention relates to nucleic acid sequences encoding ADNF III polypeptides; ADNF III polypeptides encoded by such nucleic acid sequences; antibodies to ADNF III polypeptides; and methods of using such ADNF III polypeptides for the treatment of neurological deficiencies and for the prevention of cell death associated with (1) gp120, the envelope protein from HIV; (2) N-methyl-D-aspartic acid (excito-toxicity); (3) tetrodotoxin (blockage of electrical activity); and (4) β-amyloid peptide, a substance related to neuronal degeneration in Alzheimer's disease.

Orally Active Peptides That Prevent Cell Damage And Death
view source
US Patent:

7384908, Jun 10, 2008
Filed:

Aug 17, 2000
Appl. No.:

10/049587
Inventors:

Douglas E. Brenneman - Damascus MD, US
Catherine Y. Spong - Arlington VA, US
Illana Gozes - Ramat Hasharon, IL
Albert Pinhasov - Tel Aviv, IL
Eliezer Giladi - Ramat Poleg, IL
Assignee:

National Institute of Health - Rockville MD
International Classification:

A01N 37/18
A61K 38/00
US Classification:

514 2, 514 15, 530300
Abstract:

This invention provides an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. The invention also provides a pharmaceutical composition comprising an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. In particular, the pharmaceutical composition of the invention is orally active. The invention further provides methods for reducing neuronal cell death, methods for reducing oxidative stress, and methods for reducing a condition associated with fetal alcohol syndrome using the ADNF polypeptides and the pharmaceutical compositions of the invention.

Neurothrophic Components Of The Adnf I Complex
view source
US Patent:

7427590, Sep 23, 2008
Filed:

Sep 12, 2002
Appl. No.:

10/489515
Inventors:

Douglas E. Brenneman - North Wales PA, US
Raquel Castellon - Norwalk CA, US
Catherine Y. Spong - Arlington VA, US
Janet M. Hauser - Bethesda MD, US
Illana Gozes - Ramat Hasharon, IL
Assignee:

The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC
Ramot at Tel-Aviv University, Ltd. - Tel Aviv
International Classification:

A61K 38/03
A61K 38/04
A61K 38/08
A61K 38/10
C07K 4/12
C07K 7/06
C07K 7/08
US Classification:

514 2, 514 13, 514 15, 530300, 530323, 530326, 530328
Abstract:

This invention relates to Activity Dependent Neurotrophic Factor I complex (ADNF I complex) and polypeptides of this complex, which produce their neurotrophic effects through multiple proteases intrinsic to the ADNF I complex. The invention also relates to pharmaceutical compositions comprising ADNF I complex polypeptides, as well as methods for reducing neuronal cell death in vitro and in vivo, methods for treating oxidative stress in a patient, methods for reducing a condition associated with fetal alcohol syndrome in a subject, and methods of enhancing learning and memory both pre- and post-natally, all of which methods use the ADNF I complex polypeptides of the invention.

Post-Natal Administration Of Activity-Dependent Neurotrophic Factor-Derived Polypeptides For Enhancing Learning And Memory
view source
US Patent:

7427598, Sep 23, 2008
Filed:

May 31, 2001
Appl. No.:

10/296849
Inventors:

Catherine Y. Spong - Arlington VA, US
Douglas Brenneman - Lansdale PA, US
Illana Gozes - Ramat Hasharon, IL
Assignee:

The United States of Americas as represented by the Secretary of the Department of Health and Human Services - Washington DC
Ramot at Tel-Aviv University, Ltd. - Tel Aviv
International Classification:

A61K 38/08
A61K 38/10
US Classification:

514 16, 514 15
Abstract:

The present invention provides methods for improving performance (e. g. learning and/or memory) using (ADNF) polypeptides, by treating the subject prenatally or postnatally with an Activity Dependent Neurotrophic Factor (ADNF) polypeptide in an amount sufficient to improve postnatal learning and/or memory of the subject.